Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with moderate or severe Haemophilia A in India

Next Previous
Trial Profile

Safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with moderate or severe Haemophilia A in India

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Turoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Acronyms guardian TM 10
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 14 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 05 Dec 2018 Planned End Date changed from 23 May 2019 to 22 Apr 2019.
    • 05 Dec 2018 Planned primary completion date changed from 23 Apr 2019 to 25 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top